Watch a presentation by Ram May-Ron, Managing Partner, FreeMind Group.
Ram presented during the 10th Annual Non-dilutive Funding Summit that took place in San Francisco on January 14, 2015. In his presentation Ram discussed the state of the non-dilutive funding market as it relates to industry and the Billions of dollars that are available. Ram also took a more strategic look at such a funding effort with an emphasis on a multi-submission funding strategy.
The Non-Dilutive Funding Summit came together on January 14th, 2015 for the tenth consecutive year. The ~300 life science executives who attended the day long activities learned about Neuroscience Funding Opportunities related to the mission of the National Institute of Neurological Disorders and Stroke (NINDS) from Dr Rajesh Ranganathan, as well as a detailed description of the resources available to industry by the National Institute of Allergy and Infectious Diseases (NIAID) from Dr Shy Shorer.
Dr Ranganathan described the newly issued CREATE funding opportunities and emphasized the interest NINDS has with solutions stemming from the industry side as well as urged companies to approach the NINDS before submitting a grant proposal. The purpose would be to received feedback and perhaps guidance on how to maximize the chances for an award.
During the event a panel discussion with CEOs of companies who have been successful in winning awards from $150,000 to $21,000,0000 shared their insight into the makings of a winning application. All agreed external help is warranted (coincidentally all received such assistance from the FreeMind Group) and that a diligent approach together with a sound multi-submission strategy is the way to go. FreeMind’s VP Ayal Ronen concluded the panel with pointing out that all awards have one thing in common which is that they all were submitted at certain point in time. The crowd erupted in laughter and the summit adjourned.
Jokes aside, FreeMind’s Managing Partner Ram May-Ron in his presentation focused on a balanced funding campaign where Non-Dilutive Funding must be an integral part of any funding effort. In fact, for every dollar one raises from non-dilutive sources, one can expect $8.38 dollars investment by the private sector. Meghan Norvell from nanoMR agreed interest from potential buyers increased dramatically following the award from BARDA.
Join us next year at the 11th Annual Non-Dilutive Funding Summit!
[vc_row][vc_column width=”1/1″][pt_heading h=”H1″ heading=”Non-Dilutive Funding Summit” text_align=”align-left”][pt_marginblock measure=”px”]50[/pt_marginblock][pt_leadtext text_align=”align-left”]
Join over 400 life science industry leaders in a full day of non-dilutive funding activities at the 10th Annual Non-dilutive Funding Summit, taking place on Wednesday January 14th, 2015 at the Nikko Hotel San Francisco.
The summit is proud to host Dr. Rajesh Ranganathan, the Director of the Office of Translational Research at the National Institute of Neurological Disorders and Stroke (NINDS; NIH) who will describe the NINDS and NIH funding opportunities and other resources available to the community that facilitate and enhance biomedical technology development towards commercialization.
[/pt_leadtext][pt_marginblock measure=”px”]50[/pt_marginblock][vc_button title=”Event Website” target=”_blank” color=”wpb_button” icon=”none” size=”btn-large” href=”http://freemindgroup.wpengine.com/10th-annual-non-dilutive-funding-summit-2/”][vc_button title=”Register Now!” target=”_blank” color=”btn-primary” icon=”none” size=”btn-large” href=”https://www.eventbrite.com/e/10th-annual-non-dilutive-funding-summit-tickets-10802674089″][/vc_column][/vc_row]
| Date | Title |
| July 16th | Biodefense and Infectious Diseases Non-dilutive Funding |
| July 23rd | RO1 and R21s for Companies |
| July 30th | Non-Dilutive funding for Non-US applicants |
| August 6th | Cancer Non-dilutive Funding |
| August 13th | CNS/PNS Related Non-Dilutive Funding Opportunities |
| August 20th | Details of a Detailed Budget; Accurately Constructed and well Justified |
| August 27th | Medical Device Non-Dilutive Funding: Trends & Opportunities |
| September 3rd | SBIR/STTR |
| September 10th | Registration ins and outs; smooth sailing to an error free submission |
| 08:00 | Pre-Conference Workshop – RO1 for CompaniesAyal RonenVice President, FreeMind Group |
SBIR/STTR awards account for roughly $750M directed at small businesses. An additional $600M are awarded through other mechanisms. Learn from the experts how to maximize your funding potential |
| 08:30 | Breakfast and Networking | |
| 09:00 | Welcome Remarks CONNECTGreg MckeeCEO, CONNECT |
CONNECT is a regional program that catalyzes the creation of innovative technology and life sciences products in San Diego County by linking inventors and entrepreneurs with the resources they need for success |
| 09:15 | Presentation: Non-Dilutive Funding Driving Innovation in the Private SectorRam May-Ron Managing Partner, FreeMind Group |
For profit entities are eligible for the majority of the $50B allocated annually via non-dilutive sources of funding which are considered a powerful force driving innovation in the private sector. Learn more during the presentation by Ram May-Ron from the FreeMind Group |
| 10:15 | Break | |
| 10:30 | Presentation: IP Protection in an “Open Science” Environment Michael Kinkelaar Partner at Procopio, Cory, Hargreaves & Savitch |
The Bayh-Dole Act which has protected and encouraged transformative, breakthrough research. However, it was not originally designed with “Open Science” in mind. When should institutions seek outside IP counsel? Share your experiences and join this discussion |
| 11:00 | Meet a non-dilutive funding expert | To schedule a 1×1 meeting with a funding expert click here |
| 12:00 | Break | |
| 1:00 | Presentation: Non-Dilutive Sources of Funding for Non-US ApplicantsAyal Ronen Vice President, FreeMind Group |
Every year NIH alone awards over $1,3B to non-US organizations. Learn how to target such sources as well as maximize your chances for award |
| 2:00 | Meet a non-dilutive funding expert | To schedule a 1×1 meeting with a funding expert click here |
!NIH/DOD Non-dilutive Funding Opportunities; Non-US Applicants are Welcome
Presenter: Ayal Ronen, Vice President, FreeMind Group
|
Agenda: |
|
| 9:00-09:30 | Registration and networking breakfast |
| 09:30-10:30 | Presentation |
| 10:30-10:45 | Q&A |
| 11:00-12:00 | Meet the expert – 1X1 meetings with the FreeMind team |
Presentation Outline
Currently, the National Institutes of Health (NIH) are actively funding 1,124 projects amounting to $1.3B, taking place outside the US and awarded to non-US applicant organizations. And, when taking into account collaborations and partnerships between domestic and foreign entities, the funded R&D dollars outside the US even exceed the above.
In this presentation Ayal Ronen, FreeMind’s Vice President will provide insight into the non-dilutive funding landscape with an emphasis on the NIH, Department of Defense and other government agencies. Mr. Ronen will describe the various pockets of money available for non-US applicants, potential for funding, and means to maximize chances for award.
To schedule a 1X1 meeting with Ayal Ronen, please contact:
Carla Hamoy at: carla@freemindconsultants.com, 617-6480340 ext 249
The FreeMind Group and the 9th Annual Non-Dilutive Funding Summit is proud to host Dr. Anthony Boccanfuso, Executive Director, The National Academies’ University-Industry Demonstration Partnership (UIDP) who will discuss in his presentation industry-academic collaborations and how the life science industry can leverage such ties to secure non-diltuive capital to fund their R&D activities.
Following the presentation, Dr. Boccanfuso will lead a panel discussion featuring top industry executives who will detail how non-dilutive funding substantially assisted in maintaining a sustainable business while promoting their R&D efforts.
Panelists:
Dr. Eric Patzer
Founder and President, Aridis Pharmceuticals
Dr. Scott Thatcher
CEO & Founder, Orphagen
Dr. Timothy A Antaya
CEO, Antaya Science and Technology
James Knighton
CEO, AvidBiotics
FreeMind Group and the 9th Annual Non-Dilutive Funding Summit are proud to host Dr. Larry Mahan of the National Heart, Lung, and Blood Institute (NHLBI; NIH) who will share her insight into the NHLBI’s interests and funding agenda, as well as the NIH funding opportunities and other resources available to the community that facilitate and enhance biomedical technology development towards commercialization.
The 9th Annual Non-dilutive Funding Summit is proud to host Ram May-Ron, Managing Partner, FreeMind Group who will give a presentation on a “2014 Non-Dilutive Funding Forecast”. In his presentation Mr May-Ron will share his insight into Life Science funding trends and specifically non-dilutive funding as the driving force in this sector.
[vc_row][vc_column width=”1/1″][pt_heading h=”h3″ heading=” Join over 250 life science industry leaders in a full day of non-dilutive funding activities at the 9th Annual Non-dilutive Funding Summit, taking place on Wednesday January 15th, 2014 at the Nikko Hotel San Francisco. ” text_align=”align-left”][/vc_column][/vc_row][vc_row][vc_column width=”1/1″][vc_separator][/vc_column][/vc_row][vc_row][vc_column width=”1/1″][pt_text text_align=”align-left”]
[/pt_text][/vc_column][/vc_row][vc_row][vc_column width=”1/3″][/vc_column][vc_column width=”1/3″][vc_button title=”Register Now!” target=”_blank” color=”btn-danger” icon=”none” size=”btn-large” href=”https://events.r20.constantcontact.com/register/eventReg?oeidk=a07e8bm1j5f69330bd6&oseq=&c=&ch=”][/vc_column][vc_column width=”1/3″][/vc_column][/vc_row]
FreeMind Group
6 Liberty Square #2783
Boston, MA 02109
We use cookies to gather web statistics that help us improve our site. We store no personal details.
OKLearn moreWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy